The research team led by XIA Hongguang from the Zhejiang University School of Medicine/ Liangzhu Laboratory published their latest findings in an open-access article entitled “ARIH1 Signaling Promotes Anti-tumor Immunity by Targeting PD-L1 for Proteasomal Degradation” in the journal Nature Communications on April 20. In this study, researchers screened out several compounds as inducers of PD-L1 degradation, identified ARIH1 as the E3 ubiquitin ligase responsible for targeting PD-L1 to degradation and delineated the mechanism of PD-L1 degradation and cancer escape from immunity via EGFR-GSK3α-ARIH1 signaling. This study suggests that ARIH1 might become a potential drug target to boost immunotherapy.
Over recent decades, A. baumannii has emerged as a major global hospital-acquired pathogen. Bloodstream infections (BSIs) caused by this bacterium carry a mortality rate of up to 60% and imp...
SAHZU Neurologist Prof. LOU Min and her team recently found that, despite an increased risk of symptomatic intracranial hemorrhage, intravenous alteplase provided functional benefit to acute ischemic ...
The genome, made up of DNA, contains not only protein-coding sequences but also a vast array of non-coding regulatory sequences. These two types of sequence work in concert to shape the complex phenot...
